Skip to main content
SpringerLink
Log in

Dose fractionation in 131I-metaiodobenzylguanidine (MIBG) therapy: should the tumour biology and intent of therapy be the guide?

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Postema EJ, McEwan AJ. Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults. Cancer Biother Radiopharm 2009;24(5):519–25.

    Article  CAS  PubMed  Google Scholar 

  2. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma, and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf ) 2001;55:47–60.

    Article  CAS  Google Scholar 

  3. Bomanji JB, Wong W, Gaze MN, Cassoni A, Waddington W, Solano J, et al. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol) 2003;15:193–8.

    CAS  Google Scholar 

  4. Buscombe JR, Cwikla JB, Caplin ME, Hilson AJ. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun 2005;26:969–76.

    Article  CAS  PubMed  Google Scholar 

  5. Gedik GK, Hoefnagel CA, Bais E, Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008;35:725–33.

    Article  CAS  PubMed  Google Scholar 

  6. Sywak MS, Pasieka JL, McEwan A, Kline G, Rorstad O. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J Surg 2004;28:1157–62.

    Article  PubMed  Google Scholar 

  7. Basu S, Nair N. Stable disease and improved health-related quality of life (HRQoL) following fractionated low dose 131I-metaiodobenzylguanidine (MIBG) therapy in metastatic paediatric paraganglioma: observation on false “reverse” discordance during pre-therapy work up and its implication for patient selection for high dose targeted therapy. Br J Radiol 2006;79(944):e53–8.

    Article  CAS  PubMed  Google Scholar 

  8. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 2008;52(4):403–18.

    CAS  PubMed  Google Scholar 

  9. de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008;44(4):551–6.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Medicine Centre (B.A.R.C), Tata Memorial Hospital Annexe, Parel, Mumbai, 400012, India

    Sandip Basu

Authors
  1. Sandip Basu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandip Basu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basu, S. Dose fractionation in 131I-metaiodobenzylguanidine (MIBG) therapy: should the tumour biology and intent of therapy be the guide?. Eur J Nucl Med Mol Imaging 37, 1798–1799 (2010). https://doi.org/10.1007/s00259-010-1530-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-010-1530-1

Keywords

Search

Navigation